Michael Wirtenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael Wirtenberger has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Barbara Burwinkel
Division of Molecular Genetic Epidemiology Heidelberg, Germany 2 Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center (DKFZ) Heidelberg, Germany
6 shared publicationsKari Hemminki
Division of Molecular Genetic Epidemiology Heidelberg, Germany 3 Department of Biosciences at Novum, Karolinska Institute Huddinge, Sweden
6 shared publicationsBarbara Wappenschmidt
Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics Center of Molecular Medicine Cologne (CMMC), University Hospital of Cologne
4 shared publicationsClaus R. Bartram
Institute of Human Genetics, University of Heidelberg Heidelberg
4 shared publicationsRita K. Schmutzler
Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics Center of Molecular Medicine Cologne (CMMC), University Hospital of Cologne
4 shared publicationsAlfons Meindl
Department of Gynaecology and Obstetrics, Klinikum rechts der Isar at the Technical University Munich
3 shared publications
Latest Publications
- Open Access
- 1 January 2007
- Published by Springer Nature in BMC Genomics
- Vol. 8 (1) , 77
Allelotyping of pooled DNA with 250 K SNP microarrays
Genotyping technologies for whole genome association studies are now available. To perform such studies to an affordable price, pooled DNA can be used. Recent studies have shown that GeneChip Human Mapping 10 K and 50 K arrays are suitable for the estimation of the allele frequency in pooled DNA. In the present study, we tested the accuracy of the 250 K Nsp array, which is part of the 500 K array set representing 500,568 SNPs. Furthermore, we compared different algorithms to estimate allele frequencies of pooled DNA. We could confirm that the polynomial based probe specific correction (PPC) was the most accurate method for allele frequency estimation. However, a simple k-correction, using the relative allele signal (RAS) of heterozygous individuals, performed only slightly worse and provided results for more SNPs. Using four replicates of the 250 K array and the k-correction using heterozygous RAS values, we obtained results for 104.141 SNPs. The correlation between estimated and real allele frequency was 0.983 and the average error was 0.046, which was comparable to the results obtained with the 10 K array. Furthermore, we could show how the estimation accuracy depended on the SNP type (average error for A/T SNPs: 0.043 and for G/C SNPs: 0.052). The combination of DNA pooling and analysis of single nucleotide polymorphisms (SNPs) on high density microarrays is a promising tool for whole genome association studies.
- 1 January 2007
- Published by Springer Nature in BMC Genomics
- Vol. 8 (1) , 77
Open AccessAllelotyping of pooled DNA with 250 K SNP microarrays
Genotyping technologies for whole genome association studies are now available. To perform such studies to an affordable price, pooled DNA can be used. Recent studies have shown that GeneChip Human Mapping 10 K and 50 K arrays are suitable for the estimation of the allele frequency in pooled DNA. In the present study, we tested the accuracy of the 250 K Nsp array, which is part of the 500 K array set representing 500,568 SNPs. Furthermore, we compared different algorithms to estimate allele frequencies of pooled DNA. We could confirm that the polynomial based probe specific correction (PPC) was the most accurate method for allele frequency estimation. However, a simple k-correction, using the relative allele signal (RAS) of heterozygous individuals, performed only slightly worse and provided results for more SNPs. Using four replicates of the 250 K array and the k-correction using heterozygous RAS values, we obtained results for 104.141 SNPs. The correlation between estimated and real allele frequency was 0.983 and the average error was 0.046, which was comparable to the results obtained with the 10 K array. Furthermore, we could show how the estimation accuracy depended on the SNP type (average error for A/T SNPs: 0.043 and for G/C SNPs: 0.052). The combination of DNA pooling and analysis of single nucleotide polymorphisms (SNPs) on high density microarrays is a promising tool for whole genome association studies.
- Open Access
- 8 July 2006
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 28 (2) , 423-426
The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer
Overexpression of cAMP-dependent protein kinase A (PKA) is a hallmark of the great majority of human cancers including breast cancer. A-kinase anchoring proteins (AKAPs) coordinate the specificity of PKA signalling by localizing the kinase to its subcellular sites. We tested the hypothesis whether the functional amino acid exchange Ile 646 Val , located in the kinase-binding domain of AKAP10, is a low-penetrance familial breast cancer risk factor. Ile 646 Val alters the binding of AKAP10 to PKA and is associated with morbidity. The analysis of 787 BRCA1/2 mutation-negative familial breast cancer patients and 993 controls revealed an association of the AKAP10 Ile 646 Val polymorphism with increased familial breast cancer risk [odds ratio (OR) = 1.25, 95% confidence interval (CI) 1.03–1.51, P = 0.024]. Our previous study has shown that AKAP13 Lys 526 Gln is associated with familial breast cancer (OR = 1.58). Here, we discovered that carriers of both variants, AKAP10 Ile 646 Val and AKAP13 Lys 526 Gln, are at a further enhanced breast cancer risk (OR = 2.41, 95% CI 1.30–4.46, P = 0.005). PKA is a major target of therapeutic anticancer strategies. Phosphorylation of the estrogen receptor (ER) α by PKA induces resistance against the anti-estrogen tamoxifen. Our results indicate for the first time the importance of AKAP10 Ile 646 Val for familial breast cancer susceptibility. Due to the impact of Ile 646 Val on the subcellular localization of PKA, it will be interesting to investigate whether this polymorphism influences the effectiveness of PKA and tamoxifen based therapeutic anticancer concepts.
- 8 July 2006
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 28 (2) , 423-426
Open AccessThe functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer
Overexpression of cAMP-dependent protein kinase A (PKA) is a hallmark of the great majority of human cancers including breast cancer. A-kinase anchoring proteins (AKAPs) coordinate the specificity of PKA signalling by localizing the kinase to its subcellular sites. We tested the hypothesis whether the functional amino acid exchange Ile 646 Val , located in the kinase-binding domain of AKAP10, is a low-penetrance familial breast cancer risk factor. Ile 646 Val alters the binding of AKAP10 to PKA and is associated with morbidity. The analysis of 787 BRCA1/2 mutation-negative familial breast cancer patients and 993 controls revealed an association of the AKAP10 Ile 646 Val polymorphism with increased familial breast cancer risk [odds ratio (OR) = 1.25, 95% confidence interval (CI) 1.03–1.51, P = 0.024]. Our previous study has shown that AKAP13 Lys 526 Gln is associated with familial breast cancer (OR = 1.58). Here, we discovered that carriers of both variants, AKAP10 Ile 646 Val and AKAP13 Lys 526 Gln, are at a further enhanced breast cancer risk (OR = 2.41, 95% CI 1.30–4.46, P = 0.005). PKA is a major target of therapeutic anticancer strategies. Phosphorylation of the estrogen receptor (ER) α by PKA induces resistance against the anti-estrogen tamoxifen. Our results indicate for the first time the importance of AKAP10 Ile 646 Val for familial breast cancer susceptibility. Due to the impact of Ile 646 Val on the subcellular localization of PKA, it will be interesting to investigate whether this polymorphism influences the effectiveness of PKA and tamoxifen based therapeutic anticancer concepts.
- Open Access
- 15 May 2006
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (11) , 2201-2208
Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer
The mitogen effect of the ovarian steroid estrogen is a strong risk factor for breast cancer development. This effect is mainly mediated by the estrogen receptor α, a hormone inducible transcription factor, which activates gene expression through recruiting multiple coactivators, such as PPARGC1A, PPARGC1B and EP300. We tested the hypothesis that non-conservative, putative functional amino acid exchanges in PPARGC1A, PPARGC1B and EP300 act as low-penetrance familial breast cancer risk factors. The analysis of 816 BRCA1/2 mutation-negative familial breast cancer patients and 1012 controls revealed an association of the PPARGC1A Thr 612 Met polymorphism with familial breast cancer (OR = 1.35, 95% CI 1.00–1.81, P = 0.049), high-risk familial breast cancer (OR = 1.51, 95% CI 1.08–2.12, P = 0.017) and bilateral familial breast cancer (OR = 2.30, 95% CI 1.24–4.28, P = 0.009). Logistic regression analyses of the PPARGC1B Ala 203 Pro variant showed an increased familial breast cancer risk of heterozygous and homozygous variant allele carriers (OR = 1.48, 95% CI 1.15–1.91, P = 0.002). The genotype-combination analysis of the associated PPARGC1A Thr 612 Met variant and the associated PPARGC1B Ala 203 Pro variant suggests an allele dose-dependent breast cancer risk ( Ptrend = 0.0004). Our results indicate for the first time the importance of inherited variants in the estrogen receptor coactivator genes PPARGC1A and PPARGC1B for familial breast cancer susceptibility. Owing to their impact on estrogen signaling, these polymorphisms might also influence adjuvant anti-estrogen therapy, using agents such as tamoxifen and raloxifen, and outcome of breast cancer patients.
- 15 May 2006
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (11) , 2201-2208
Open AccessAssociations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer
The mitogen effect of the ovarian steroid estrogen is a strong risk factor for breast cancer development. This effect is mainly mediated by the estrogen receptor α, a hormone inducible transcription factor, which activates gene expression through recruiting multiple coactivators, such as PPARGC1A, PPARGC1B and EP300. We tested the hypothesis that non-conservative, putative functional amino acid exchanges in PPARGC1A, PPARGC1B and EP300 act as low-penetrance familial breast cancer risk factors. The analysis of 816 BRCA1/2 mutation-negative familial breast cancer patients and 1012 controls revealed an association of the PPARGC1A Thr 612 Met polymorphism with familial breast cancer (OR = 1.35, 95% CI 1.00–1.81, P = 0.049), high-risk familial breast cancer (OR = 1.51, 95% CI 1.08–2.12, P = 0.017) and bilateral familial breast cancer (OR = 2.30, 95% CI 1.24–4.28, P = 0.009). Logistic regression analyses of the PPARGC1B Ala 203 Pro variant showed an increased familial breast cancer risk of heterozygous and homozygous variant allele carriers (OR = 1.48, 95% CI 1.15–1.91, P = 0.002). The genotype-combination analysis of the associated PPARGC1A Thr 612 Met variant and the associated PPARGC1B Ala 203 Pro variant suggests an allele dose-dependent breast cancer risk ( Ptrend = 0.0004). Our results indicate for the first time the importance of inherited variants in the estrogen receptor coactivator genes PPARGC1A and PPARGC1B for familial breast cancer susceptibility. Owing to their impact on estrogen signaling, these polymorphisms might also influence adjuvant anti-estrogen therapy, using agents such as tamoxifen and raloxifen, and outcome of breast cancer patients.
- 1 March 2006
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 78 (3) , 520-522
Identification of Frequent Chromosome Copy-Number Polymorphisms by Use of High-Resolution Single-Nucleotide–Polymorphism Arrays
- 1 March 2006
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 78 (3) , 520-522
Identification of Frequent Chromosome Copy-Number Polymorphisms by Use of High-Resolution Single-Nucleotide–Polymorphism Arrays
- Open Access
- 18 October 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 593-598
Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer
The A-kinase anchor protein 13 (AKAP13, alias BRX and lbc) tethers cAMP-dependent protein kinase to its subcellular environment and catalyses Rho GTPases activity as a guanine nucleotide exchange factor. The crucial role of members of the Rho family of GTPases in carcinogenesis is well established and targeting Rho proteins with antineoplastic compounds has become a major effort in the fight against cancer. Thus, genetic alterations within the candidate cancer susceptibility gene AKAP13 would be expected to provoke a constitutive Rho signalling, thereby facilitating the development of cancer. Here, we analysed the potential impact of four polymorphic non-conservative amino acid exchanges ( Arg 494 Trp , Lys 526 Gln , Asn 1086 Asp and Gly 2461 Ser ) in AKAP13 on familial breast cancer. We performed a case–control study using genomic DNA of BRCA1/2 mutation-negative German female index patients from 601 unrelated families, among a subset of 356 high-risk families, and 1053 German female unrelated controls. The newfound Lys 526 Gln polymorphism revealed a significant association with familial breast cancer (OR = 1.58, 95% CI = 1.07–2.35) and an even stronger association with high-risk familial breast cancer (OR = 1.85, 95% CI = 1.19–2.88). Haplotype analyses were in line with genotype results displaying a similar significance as analyses of individual polymorphisms. Due to the pivotal role of AKAP13 in the Rho GTPases signalling network, this variant might affect the susceptibility to other cancers as well.
- 18 October 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 593-598
Open AccessAssociation of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer
The A-kinase anchor protein 13 (AKAP13, alias BRX and lbc) tethers cAMP-dependent protein kinase to its subcellular environment and catalyses Rho GTPases activity as a guanine nucleotide exchange factor. The crucial role of members of the Rho family of GTPases in carcinogenesis is well established and targeting Rho proteins with antineoplastic compounds has become a major effort in the fight against cancer. Thus, genetic alterations within the candidate cancer susceptibility gene AKAP13 would be expected to provoke a constitutive Rho signalling, thereby facilitating the development of cancer. Here, we analysed the potential impact of four polymorphic non-conservative amino acid exchanges ( Arg 494 Trp , Lys 526 Gln , Asn 1086 Asp and Gly 2461 Ser ) in AKAP13 on familial breast cancer. We performed a case–control study using genomic DNA of BRCA1/2 mutation-negative German female index patients from 601 unrelated families, among a subset of 356 high-risk families, and 1053 German female unrelated controls. The newfound Lys 526 Gln polymorphism revealed a significant association with familial breast cancer (OR = 1.58, 95% CI = 1.07–2.35) and an even stronger association with high-risk familial breast cancer (OR = 1.85, 95% CI = 1.19–2.88). Haplotype analyses were in line with genotype results displaying a similar significance as analyses of individual polymorphisms. Due to the pivotal role of AKAP13 in the Rho GTPases signalling network, this variant might affect the susceptibility to other cancers as well.
- 3 June 2005
- Published by Springer Nature in Human Genetics
- Vol. 117 (4) , 389-397
SNP microarray analysis for genome-wide detection of crossover regions
There is a great deal of interest in understanding the non-random distribution of recombination events over the human genome, because it has important implications for using linkage disequilibrium (LD) to identify human disease genes. So far, only a few recombination hotspots in the human genome have been characterised and the identification of new crossover hotspots will contribute to a better understanding of the mechanisms that govern their formation and distribution. This study shows that high-density single nucleotide polymorphism (SNP) arrays, together with the presented analysis method, are an appropriate tool for generating a whole-genome recombination pattern and for detecting new crossover regions with enhanced recombination frequency. Based on the genotype data of 16 members of a Caucasian three-generation family, we identified 825 crossover regions. The average recombination frequency of females and males was 0.77 and 0.56 cM/Mb, respectively. We detected 24 crossover regions showing elevated recombination activity, which comprised known hotspots, like the MHC II region, confirming the non-random distribution of recombination events along the genome. Interestingly, 29.2% of the identified crossover hotspot regions overlapped with regions flanked by segmental duplications published by Bailey et al. (Science 297:1003–1007, 2002) suggesting that segmental duplications and crossover hotspot regions are mechanistically linked. By extrapolating the results of the present study, we conclude that it might be feasible, at least in part, to estimate to what extent the block-like pattern of LD exactly relies on the genome-wide crossover pattern using the next generation high-density SNP microarrays.
- 3 June 2005
- Published by Springer Nature in Human Genetics
- Vol. 117 (4) , 389-397
SNP microarray analysis for genome-wide detection of crossover regions
There is a great deal of interest in understanding the non-random distribution of recombination events over the human genome, because it has important implications for using linkage disequilibrium (LD) to identify human disease genes. So far, only a few recombination hotspots in the human genome have been characterised and the identification of new crossover hotspots will contribute to a better understanding of the mechanisms that govern their formation and distribution. This study shows that high-density single nucleotide polymorphism (SNP) arrays, together with the presented analysis method, are an appropriate tool for generating a whole-genome recombination pattern and for detecting new crossover regions with enhanced recombination frequency. Based on the genotype data of 16 members of a Caucasian three-generation family, we identified 825 crossover regions. The average recombination frequency of females and males was 0.77 and 0.56 cM/Mb, respectively. We detected 24 crossover regions showing elevated recombination activity, which comprised known hotspots, like the MHC II region, confirming the non-random distribution of recombination events along the genome. Interestingly, 29.2% of the identified crossover hotspot regions overlapped with regions flanked by segmental duplications published by Bailey et al. (Science 297:1003–1007, 2002) suggesting that segmental duplications and crossover hotspot regions are mechanistically linked. By extrapolating the results of the present study, we conclude that it might be feasible, at least in part, to estimate to what extent the block-like pattern of LD exactly relies on the genome-wide crossover pattern using the next generation high-density SNP microarrays.
- Open Access
- 31 May 2005
- Published by Wiley in International Journal of Cancer
- Vol. 117 (4) , 638-642
c-MYC Asn11Ser is associated with increased risk for familial breast cancer
C‐MYC is a multifaceted protein that regulates cell proliferation, differentiation and apoptosis. Its crucial role in diverse cancers has been demonstrated in several studies. Here, we analysed the influence of the rare c‐MYC Asn11Ser polymorphism on familial breast cancer risk by performing a case‐control study with a Polish (cases n = 349; controls n = 441) and a German (cases n = 356; controls n = 655) study population. All cases have been tested negative for mutations in the BRCA1 and BRCA2 genes. A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05–2.26, p = 0.028). The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20–4.21, p = 0.012). The wild‐type amino acid Asn of this polymorphism is located in the N‐terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N‐MYC homologue. Due to the pivotal role of c‐MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.
- 31 May 2005
- Published by Wiley in International Journal of Cancer
- Vol. 117 (4) , 638-642
Open Accessc-MYC Asn11Ser is associated with increased risk for familial breast cancer
C‐MYC is a multifaceted protein that regulates cell proliferation, differentiation and apoptosis. Its crucial role in diverse cancers has been demonstrated in several studies. Here, we analysed the influence of the rare c‐MYC Asn11Ser polymorphism on familial breast cancer risk by performing a case‐control study with a Polish (cases n = 349; controls n = 441) and a German (cases n = 356; controls n = 655) study population. All cases have been tested negative for mutations in the BRCA1 and BRCA2 genes. A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05–2.26, p = 0.028). The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20–4.21, p = 0.012). The wild‐type amino acid Asn of this polymorphism is located in the N‐terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N‐MYC homologue. Due to the pivotal role of c‐MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.